Trials / Recruiting
RecruitingNCT06304103
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
An Efficacy and Safety Study of AND017 for the Treatment of Anemia Due to Lower Risk Myelodysplastic Syndromes (MDS)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- Kind Pharmaceuticals LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, multicenter, randomized, open-lable, dose ranging study to evaluate the efficacy and safety of AND017 for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS) in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AND017 | Administer AND017 once per day (QD) |
Timeline
- Start date
- 2025-03-14
- Primary completion
- 2026-12-01
- Completion
- 2027-05-01
- First posted
- 2024-03-12
- Last updated
- 2026-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06304103. Inclusion in this directory is not an endorsement.